SVB Wealth LLC Purchases 26,154 Shares of Boston Scientific Corporation $BSX

SVB Wealth LLC increased its holdings in Boston Scientific Corporation (NYSE:BSX – Free Report) by 457.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 31,868 shares of the medical equipment provider’s stock after purchasing an additional 26,154 shares during the quarter. SVB Wealth LLC’s holdings in Boston Scientific were worth $1,391,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of BSX. BlackRock Inc. bought a new position in Boston Scientific during the 2nd quarter valued at approximately $5,534,781,000. Primecap Management Co. CA bought a new stake in shares of Boston Scientific in the 2nd quarter worth approximately $2,156,233,000. Janus Henderson Group PLC grew its position in shares of Boston Scientific by 31.0% in the 1st quarter. Janus Henderson Group PLC now owns 16,497,366 shares of the medical equipment provider’s stock worth $1,035,202,000 after buying an additional 3,907,981 shares during the last quarter. Amundi increased its stake in shares of Boston Scientific by 13.8% during the first quarter. Amundi now owns 14,122,913 shares of the medical equipment provider’s stock valued at $886,213,000 after buying an additional 1,707,754 shares during the period. Finally, Arrowstreet Capital Limited Partnership increased its stake in shares of Boston Scientific by 25.9% during the first quarter. Arrowstreet Capital Limited Partnership now owns 13,891,668 shares of the medical equipment provider’s stock valued at $871,702,000 after buying an additional 2,856,040 shares during the period. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Down 0.0%

BSX stock opened at $44.33 on Monday. Boston Scientific Corporation has a fifty-two week low of $39.57 and a fifty-two week high of $104.61. The business’s 50 day moving average price is $44.00 and its two-hundred day moving average price is $54.50. The company has a debt-to-equity ratio of 0.42, a quick ratio of 0.81 and a current ratio of 1.36. The company has a market capitalization of $64.25 billion, a price-to-earnings ratio of 18.78, a price-to-earnings-growth ratio of 1.31 and a beta of 0.60.

Boston Scientific (NYSE:BSX – Get Free Report) last announced its earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.73. The firm had revenue of $5.14 billion during the quarter, compared to analyst estimates of $5.09 billion. Boston Scientific had a return on equity of 18.61% and a net margin of 16.62%. The business’s revenue was up 1.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.75 EPS. As a group, analysts forecast that Boston Scientific Corporation will post 3.17 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Leerink Partners decreased their target price on Boston Scientific from $55.00 to $50.00 and set an “outperform” rating for the company in a report on Thursday, October 29th. Truist Financial cut their price target on shares of Boston Scientific from $57.00 to $51.00 and set a “buy” rating on the stock in a report on Wednesday, October 14th. BTIG Research reduced their price objective on shares of Boston Scientific from $56.00 to $49.00 and set a “buy” rating on the stock in a research report on Thursday, October 29th. UBS Group decreased their price objective on shares of Boston Scientific from $67.00 to $57.00 and set a “buy” rating for the company in a report on Thursday, October 29th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Boston Scientific in a research report on Friday, October 2nd. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $61.43.

Get Our Latest Research Report on BSX

About Boston Scientific

(Free Report)

Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts. Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.

Featured Articles

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX – Free Report).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.